Literature DB >> 9097989

Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis.

G R Heudebert1, R Marks, C M Wilcox, R M Centor.   

Abstract

BACKGROUND & AIMS: Omeprazole has shown remarkable efficacy and safety in the treatment of patients with gastroesophageal reflux disease (GERD); similarly, laparoscopic techniques have allowed less morbidity in patients undergoing fundoplication procedures. Concerns about the long-term cost and safety of both strategies have prompted a debate of their role in long-term management of patients with severe erosive esophagitis.
METHODS: A cost-utility analysis was performed to compare two strategies: laparoscopic Nissen fundoplication (LNF) vs. omeprazole. A two-stage Markov model was used to obtain cost and efficacy estimates; all estimates were discounted at 3% per year. The time horizon was 5 years. Sensitivity analyses were performed on all relevant variables.
RESULTS: Both strategies were similarly effective (4.33 quality-adjusted life years per patient), with omeprazole less expensive than LNF ($6053 vs. $9482 per patient). At 10 years, LNF and omeprazole costs were similar. Efficacy estimates were extremely sensitive to changes in quality of life associated with postoperative symptoms and long-term use of medication.
CONCLUSIONS: Medical therapy is the preferred treatment strategy for most patients with severe erosive esophagitis. Individuals with a long life expectancy are good candidates for LNF if postoperative morbidity is low and GERD symptoms remain abated for many years.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9097989     DOI: 10.1016/s0016-5085(97)70118-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  25 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

Review 2.  How should Barrett's ulceration be treated?

Authors:  J H Peters; K K Wang
Journal:  Surg Endosc       Date:  2004-01-12       Impact factor: 4.584

3.  Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease. Antagonist.

Authors:  J P Galmiche; F Zerbib
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 4.  Guidelines for surgical treatment of gastroesophageal reflux disease.

Authors:  Dimitrios Stefanidis; William W Hope; Geoffrey P Kohn; Patrick R Reardon; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2010-08-20       Impact factor: 4.584

5.  Heller myotomy vs Heller myotomy plus Dor fundoplication: cost-utility analysis of a randomized trial.

Authors:  A Torquati; R Lutfi; L Khaitan; K W Sharp; W O Richards
Journal:  Surg Endosc       Date:  2006-01-25       Impact factor: 4.584

6.  The Stretta procedure versus proton pump inhibitors and laparoscopic Nissen fundoplication in the management of gastroesophageal reflux disease: a cost-effectiveness analysis.

Authors:  Dan Comay; Viviane Adam; Ediardo B da Silveira; Wendy Kennedy; Serge Mayrand; Alan N Barkun
Journal:  Can J Gastroenterol       Date:  2008-06       Impact factor: 3.522

Review 7.  Treatment of gastro-oesophageal reflux disease in adults.

Authors:  J P Galmiche; E Letessier; C Scarpignato
Journal:  BMJ       Date:  1998-06-06

Review 8.  Cost-effectiveness of proton pump inhibitors versus laparoscopic Nissen fundoplication for patients with gastroesophageal reflux disease: a systematic review of the literature.

Authors:  Anthony S Thijssen; Ivo A M J Broeders; G Ardine de Wit; Werner A Draaisma
Journal:  Surg Endosc       Date:  2011-04-13       Impact factor: 4.584

9.  Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model.

Authors:  Joseph Romagnuolo; Michael A Meier; Daniel C Sadowski
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

10.  Outcomes of minimally invasive antireflux operations in the elderly: a comparative review.

Authors:  Hiran C Fernando; Philip R Schauer; Percival O Buenaventura; Neil A Christie; John M Close; James D Luketich
Journal:  JSLS       Date:  2003 Oct-Dec       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.